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Background:Circadian variation of joint stiffness (morning stiffness) and its impact on functional ability arewide-
ly recognised in rheumatoid arthritis. Subsequent within-day variation of walking ability is important due to the
increased availability of instrumented gait analysis. This study aimed to quantify diurnal variation of gait in pa-
tients with rheumatoid arthritis, and explore associations with disease characteristics.
Methods: Thirty one inpatients with rheumatoid arthritis walked at a self-selected speed along a GAITRite instru-
mented walkway 5 times during a single day.
Findings: Participants showed marked diurnal variation in gait, leading to a systematic variation throughout the
day (F= 19.56, P= b0.001). Gait velocity and stride length both increased, whereas the proportion of each gait
cycle spent in stance phase or double support decreased, consistent with improving function throughout the day.
Although absolute gait velocity correlated with disease characteristics, the magnitude of diurnal variation ap-
peared to be independent of disease activity (rho = 0.26, P = 0.15), disease duration (rho = −0.19, P =
0.324), and underlying functional ability (rho = 0.09, P= 0.65).
Interpretation: Although morning stiffness is well recognised in rheumatoid arthritis, this is the ﬁrst time that its
effect on gait has been quantiﬁed. Patients with rheumatoid arthritis exhibited a systematic change in walking
ability throughout the day, which was independent of disease characteristics. These ﬁndings have important im-
plications for the interpretation of existing data and the design of future studies. Repeat measures should be con-
ducted at the same time of day to exclude the effects of diurnal variation.© The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/)1. Introduction
The impact of rheumatoid arthritis (RA) on the lower limb has been
widely documented (Grondal et al., 2008; Helliwell et al., 2005;
Michelson et al., 1994). Joint destruction and deformity are common-
place in the lower limb resulting inmarked gait abnormalities and func-
tional impairment, and an associated reduction in quality of life (Turner
and Woodburn, 2008; Turner et al., 2003, 2006, 2008).
The restricted locomotor ability in patients with RA is typically man-
ifest as reduced gait velocity, an increased double support period, re-
duced stride length, and reduced cadence (Fransen et al., 1994; Turner
and Woodburn, 2008; Turner et al., 2003). These temporal and spatial
gait parameters, particularly gait velocity, are widely reported in the7866 and 18932 from Arthritis
ic and Musculoskeletal Disease,
K.
house).
. This is an open access article underliterature as objective measures of physical function and have been
shown to correlate with disease activity (Turner et al., 2008; van der
Leeden et al., 2008). In addition to being used as an objective outcome
measure in research, gait analysis is increasingly used in clinical practice
to provide an objective assessment of functional ability, to plan and op-
timise clinical interventions, and evaluate response (Barkham et al.,
2010; van der Leeden et al., 2008).
The pathophysiological processes in RA aremodulated by a complex
array of pro and anti inﬂammatory cytokineswhich showmarked circa-
dian variation (change over a 24 hour period) (Cutolo et al., 2008; Gibbs
and Ray, 2013; Straub and Cutolo, 2007). Clinical symptoms also follow
this changing pattern and there is a clear temporal relationship between
elevated levels of pro-inﬂammatory cytokines and clinical symptoms
such as morning stiffness (Cutolo et al., 2003, 2008; Gibbs and Ray,
2013). For some time there has been objective evidence of diurnal var-
iation (within day change) in upper limb function (Helliwell et al., 1988;
Herold and Günther, 1987) but to-date there has been no systematic
study of the within day variation of gait parameters.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Study ﬂow diagram.
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spatial gait parameters in patients with RA, and to explore associations
between the magnitude of variation and perceived stiffness, functional
ability, and disease activity.
2. Methods
2.1. Participants
Assenting hospital in-patients with a diagnosis of RA and with
≥30 minute morning stiffness were recruited from the rheumatology
ward. Patients were excluded if their primary lower limb/gait pathology
was not due to RA or if theywere unable to walk. Patients were allowed
to continue their normal medication but were excluded from the study
if they commenced or were scheduled to commence a new biologic or
steroid (including intra-articular injection) during the current admis-
sion and prior to the completion of gait analysis. Walking sticks and
elbow crutches were permitted where required. Ethical approval was
obtained from the Leeds West Research Ethics Committee (08/H1307/
65) and all participants provided written informed consent. All aspects
of the study were conducted in accordance with the Declaration of
Helsinki.
2.2. Data collection
The GAITRite instrumented walkway (CIR Systems Inc, USA) was
used to measure function objectively and this has been validated previ-
ously for the measurement of temporal and spatial gait parameters
(Menz et al., 2004; Rome, 2005). Patients were asked to walk at a self-
selected speed at ﬁve time points throughout the day: at waking
(0 h);+1 h;+3 h;+6 h; and+12h. The studywas undertaken along-
side normal ward activities so a window of +/−1 h was permitted for
each time point at +3 h and beyond. Preferred waking time was deter-
mined from each patient prior to entering the study but was usually be-
tween 6 am and 8 am. All patients were met on the ward at the agreed
waking time and immediately transported to the gait laboratory by
wheelchair for the 0 hour assessment, before beginningnormal daily ac-
tivities. GAITRite data were processed and analysed using the GAITRite
v3.8 software (CIR Systems Inc, Sparta, New Jersey, USA).
The patient's own perception of severity of their general stiffness
was captured at each time point using a 100 mm visual analogue scale
(VAS) anchored with “no stiffness” and “worst stiffness imaginable”.
Disease activity wasmeasured using a composite index of disease activ-
ity Disease Activity Score (DAS28) (Smolen et al., 1995), and the UK
version of Health Assessment Questionnaire Disability Index HAQ-DI
provided a measure of self reported functional ability (Kirwan and
Reeback, 1986).
2.3. Statistical analysis
Analysis was conducted on a per protocol basis, with patients failing
to complete follow-up excluded from all analysis. Summary statistics
were used to describe the demographic and clinical features of the
participants.
Diurnal variation of gait velocity, stride length, duration of stance
phase and double support (as a percentage of gait cycle) were described
using summary statistics and 95% conﬁdence intervals (95%CI). Gait ve-
locity has been shown previously to be themost sensitive temporal and
spatial gait parameter, so was explored further (Helliwell et al., 2007).
Systematic within-day changes in gait velocity were examined using a
general linear model repeated-measures ANOVA approach having
checked the residuals for normality and heteroscedasticity using
Kolmogorov–Smirnov tests and visual inspection of residuals plotted
against ﬁtted values. The threshold for statistical signiﬁcance was
set at alpha= 0.05; the Bonferroni method was used to adjust for mul-
tiple comparisons between time-points and adjusted P-values havebeen presented. To conﬁrm the ﬁndings of the parametric test, a supple-
mentary non-parametric Friedman test was performed with post-hoc
Dunn–Bonferroni pairwise comparisons between time-points.
Associations between the magnitude of change in gait velocity and
disease factors (HAQ, DAS28, and disease duration) were assessed
using Spearman's rank correlation coefﬁcient. Statistical analyses were
conducted using SPSS 21 (IBM, Armonk, New York, USA)
3. Results
3.1. Participant proﬁle
A total of 41 patients were screened for eligibility and 35 entered the
study, of whom 31 completed the ﬁnal follow-up assessment. Fig. 1
illustrates the ﬂow of patients through the study and provides reasons
for exclusions or non-completion. The 31 patients included in the anal-
ysis (11 male, 20 female) had a median age of 67 (range 35 to 87) and
their mean BMI was 25.9 (SD = 5.46). The mean disease duration was
10.5 years (range 1 to 50), and median DAS28 and HAQ were 5.39
(IQR = 3.28 to 7.50) and 2.25 (IQR = 1.46 to 3.04) respectively.
3.2. Diurnal variation
Temporal and spatial gait parameters showed systematic changes
consistent with improving physical function throughout the day
(Table 1). Gait velocity and stride length both increased, whereas
the proportion of each gait cycle spent in stance phase or double sup-
port decreased. Gait velocity, as themost sensitive parameter, exhib-
ited a large relative improvement from baseline (Fig. 2).
A repeated measures ANOVA demonstrated a systematic increase in
gait velocity throughout the day (F = 19.56, P b 0.001). Bonferroni-
adjusted post-hoc pairwise comparisons identiﬁed signiﬁcant differ-
ences between baseline and all subsequent time points (Table 2). Simi-
larly, signiﬁcant differences were also found between +12 h and all
other time points. Gait velocity was more stable between +3 and +6 h
and the difference between these time points was not signiﬁcant. Inspec-
tion of the model residuals indicated that there were borderline-
signiﬁcant departures from normality for the waking (P = 0.049)
and +12 hour measurements (P= 0.051); therefore, we repeated the
analysis using a non-parametric Friedman test. This conﬁrmed that gait
velocity differed between the time-points (P b 0.001). Pairwise tests
showed differences in gait velocity between baseline and all subsequent
time-points; using the less powerful non-parametric test, there were
Table 1
Diurnal variation of temporal and spatial parameters.
Waking +1 h +3 h +6 h +12 h
Gait velocity (cm/sec) Mean 37.64 43.75 45.52 48.01 53.03
SD 24.88 28.73 26.94 28.98 32.21
Stride length (cm) Mean 62.06 66.23 68.80 71.35 73.13
SD 26.64 28.28 26.96 28.49 30.11
Stance phase (% of gait cycle) Mean 74.28 73.08 71.98 72.19 71.12
SD 9.44 9.24 8.74 8.75 8.72
Double support (% of gait cycle) Mean 49.22 46.75 44.52 43.77 42.66
SD 18.65 18.25 16.61 16.79 17.14
Table 2
Pairwise comparison of gait velocity at different time points.
Waking + 1 h + 3 h + 6 h
+ 12 h Mean diff 15.39 9.28 7.51 4.98
Adj. sig. b0.001 0.003 0.010 0.015
+ 6 h Mean diff 10.40 4.30 2.52
Adj. sig. b0.001 0.093 0.639
+ 3 h Mean diff 7.88 1.78
Adj. sig. b0.001 1.000
+ 1 h Mean diff 6.10
Adj. sig. 0.001
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taken at baseline and +1 hour; but following correction for multiple
comparisons the +12 hour measurements did not differ from those
at +3 or +6 hours (supplementary data 1).
3.3. Correlation with disease characteristics
Absolute gait velocity correlated with HAQ and disease duration at
all time points but no correlation was found between DAS28 and abso-
lute gait velocity. Similarly, patient reported stiffness only correlated
with absolute gait velocity at waking and +1 h whereas there was no
evidence of a correlation between patient-perceived stiffness and gait
velocity beyond the ﬁrst hour (Supplementary data 2 and 3).
In contrast, the magnitude of within-day variation of gait velocity
appeared to be independent of disease factors: There was no evi-
dence of a correlation between HAQ (0.09, P = 0.65), DAS28 (0.26,
P= 0.15), or disease duration (−0.19, P= 0.32) and the magnitude
of variation in gait velocity over the course of the day.
4. Discussion
This is the ﬁrst study to quantify within-day variation of gait in pa-
tients with RA and has identiﬁed marked diurnal variation in a range
of temporal and spatial gait parameters. The continued improvement
led to a systematic difference in functional ability occurring over the
course of the day. While the absolute gait parameters correlated with
patient-reported functional ability, the magnitude of within-day varia-
tion appeared to be independent of disease activity, disease duration,
and self-reported functional ability. This indicates that repeat measures
of gait should be conducted at the same time of day to exclude the
effects of diurnal variation and also that self-reportedmeasures of func-
tional ability are not adequate surrogates for evaluating diurnal varia-
tion clinically.
This study provides useful information on the measurement of gait
in patients with RA at a timewhen instrumented gait analysis is becom-
ing increasingly widely used in clinical and research applications. There
was a clear improvement in temporal and spatial gait variables on theFig. 2. Variation in gait velocity from baseline.group level, but there was also notable between-patient variation. For
example, the group mean improvement in gait velocity from baseline
was 55%, but this ranged from a decrease of 41% through to an increase
of 397% at 12 h. This observation further reinforces the conclusion that
repeat measures should be taken at the same time of day to ensure
that any changes arising from quantifying locomotor function reﬂect a
true change in clinical status, rather than the natural diurnal variation
occurring in peoplewith RAasdescribedhere. This has importantmeth-
odological implications for the design of future studies and where gait
analysis is to be used to inform clinical decision making. These ﬁndings
should also prompt a re-evaluation of existing studies which attribute a
change in functional ability between time points to an intervention,
without controlling for diurnal variation (Conrad et al., 1996; Locke
et al., 1984; MacSween et al., 1999).
The classic pattern of stiffness in patients with RA, is one in which
stiffness is worst ﬁrst thing in the morning but then improves during
the day before returning in the evening (Scott, 1960). More recently
this pattern of symptoms and associated functional ability has been
shown to correspond to circadian variation in pro-inﬂammatory cyto-
kines (Cutolo et al., 2003, 2008; Gibbs and Ray, 2013; Helliwell et al.,
1988). This study conﬁrms that the improvement in function is sharpest
during the ﬁrst hour after waking, but walking ability continued to im-
prove throughout the 12 hour study period. There was no evidence of a
decrease in functional ability towards the end of the study day as has
been suggested by other reports (Helliwell et al., 1988; Herold and
Günther, 1987), although this may reﬂect the 12 hour study period
whereby function was not evaluated through to patients’ bed time.
This study quantiﬁed variation in gait during the day time (diurnal) as
this is when most people conduct their daily activities and are most
likely to undergo clinical gait analysis, rather than over the course of a
24 hour period (circadian).
When considering systematic improvement it should be noted that
somemeasures of functional ability, such as grip strength, are associated
with a learning effect, whereby functional ability improves over time
due to participants increasing familiarity with a previously unfamiliar
task such as using a dynamometer (Bellace et al., 2000; Reddon et al.,
1985). The possibility of a learning effect cannot be excluded from the
current study but is considered unlikely as participants are used to
walking and the GAITRite walkway does not require attachment of
any equipment to participants or learning of any special protocols.
Steps were also taken to ensure that any observed change in func-
tional ability was not the result of starting a new medication. No pa-
tients were recruited if they had, or were scheduled to commence a
new biologic or steroid (including intra-articular injection) prior to or
during the day and prior to completion of the study. This step was
taken to reduce confounding and to attempt to ensure that any ob-
served variation in gait was the result of diurnal variation rather than
a response to any new medication. Patients were able to continue
their normal medication as prescribed.
Temporal and spatial gait parameters, particularly gait velocity, are
widely reported in the literature and have previously been shown to
correlate with disease characteristics (Fransen and Edmonds, 1999;
Turner andWoodburn, 2008; Turner et al., 2003). The current study ex-
plored this relationship further and found that although absolute gait
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lationwithmeasures of disease activity. Such ﬁndings are not unexpect-
ed in a cohort with established disease. The functional ability of patients
with established disease is known to be linked more to accumulated
damage over the course of their disease, rather than being driven purely
by current disease activity (Aletaha et al., 2006; Smolen et al., 2007;
Welsing et al., 2001).
Amajor strength of the study is that it is the ﬁrst tomeasure tempo-
ral and spatial gait parameters throughout the course of a day in a co-
hort of patients with RA. The study design enabled the quantiﬁcation
of variation in gait throughout the day and at clinically meaningful
time points, thereby increasing the clinical relevance of the ﬁndings.
However, the practicalities of capturing gait at the earliest time points
necessitated that patients were already on site: the sample therefore
consisted of inpatients who were admitted as part of their ongoing
care and were among the more severely affected in the RA population.
Although this may limit the generalisability of the ﬁndings, it was nota-
ble that the magnitude of diurnal variation of gait was independent of
all disease factors including disease activity and it is likely that a similar
effect is present in out-patient populations also.
With such large within-day variation in walking ability, it would be
helpful in the future to study community dwelling participants, poten-
tially using activitymonitors to record temporal and spatial gait param-
eters over a 24 hour period. Further development of the current
generation of activity monitors appears to be required however, before
they can be used reliably in patients with RA (Backhouse et al., 2013).
In conclusion, this studyquantiﬁed, for theﬁrst time,marked diurnal
variation in temporal and spatial gait parameters in patients with rheu-
matoid arthritis. Patients showed continued improvement in function
throughout the day. Although the underlying walking ability was relat-
ed to patient-reported functional ability and disease duration, the mag-
nitude of the variation in measured gait parameters throughout the day
was independent of disease activity, disease duration, and underlying
functional ability. This study has important implications for the inter-
pretation of existing data and should inform future data collection.
This study indicates that repeat measures obtained on different days
should be conducted at the same time of day to exclude the effects of
diurnal variation.
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